Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, agosto 31
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Pacific Biosciences of California Inc
PACB
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.40
-0.15
-9.68%
al cierre: Aug 28, 5:00 PM EST
$1.42
0.02
1.43%
After hour: Aug 28, 7:48 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Pacific Biosciences Financials
Pacific Biosciences (PACB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.
Benzinga Newsdesk
PRO
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 7.69 percent decrease over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.
Benzinga Newsdesk
PRO
Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 7.69 percent. This is a 20 percent increase over losses of $(0.15) per share from
Benzinga Newsdesk
Insights into Pacific Biosciences Q4 Earnings
Benzinga Insights
PRO
Pacific Biosciences Q4 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $44.645M Beat $42.530M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 18.37 percent. This is a 40 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
Privacy Manager